HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Price & Overview
EBR:HYL • BE0974363955
Current stock price
The current stock price of HYL.BR is 4.93 EUR. Today HYL.BR is down by -0.4%. In the past month the price decreased by -25.83%. In the past year, price decreased by -14.62%.
HYL.BR Key Statistics
- Market Cap
- 138.04M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.23
- Dividend Yield
- N/A
HYL.BR Stock Performance
HYL.BR Stock Chart
HYL.BR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HYL.BR. When comparing the yearly performance of all stocks, HYL.BR is a bad performer in the overall market: 93.16% of all stocks are doing better.
HYL.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR. While HYL.BR has a great health rating, there are worries on its profitability.
HYL.BR Earnings
HYL.BR Forecast & Estimates
7 analysts have analysed HYL.BR and the average price target is 13.84 EUR. This implies a price increase of 180.69% is expected in the next year compared to the current price of 4.93.
For the next year, analysts expect an EPS growth of 54.37% and a revenue growth 113.66% for HYL.BR
HYL.BR Groups
Sector & Classification
HYL.BR Financial Highlights
Over the last trailing twelve months HYL.BR reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 0.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.99% | ||
| ROE | -23.92% | ||
| Debt/Equity | 0.05 |
HYL.BR Ownership
HYL.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.54 | 98.029B | ||
| SNW | SANOFI | 9.54 | 98.005B | ||
| 1SAN | SANOFI | 9.5 | 97.617B | ||
| UCB | UCB SA | 26.43 | 52.09B | ||
| UNC | UCB SA | 25.88 | 51.779B | ||
| MRK | MERCK KGAA | 13.47 | 49.087B | ||
| 1MRK | MERCK KGAA | 12.99 | 46.695B | ||
| BAYN | BAYER AG-REG | 8.64 | 39.768B | ||
| 1BAYN | BAYER AG-REG | 8.66 | 39.68B | ||
| IPN | IPSEN | 13.33 | 13.669B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.99 | 10.39B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.89B | ||
| VIRP | VIRBAC SA | 16.49 | 2.983B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About HYL.BR
Company Profile
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Company Info
IPO: 2020-06-29
HYLORIS PHARMACEUTICALS SA
Boulevard Patience et Beaujonc, Liege
Liege LIEGE BE
Employees: 49
Phone: 3243460207
HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ
What does HYL do?
Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. The firm focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. The company has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. The company also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
What is the stock price of HYLORIS PHARMACEUTICALS SA today?
The current stock price of HYL.BR is 4.93 EUR. The price decreased by -0.4% in the last trading session.
Does HYL stock pay dividends?
HYL.BR does not pay a dividend.
What is the ChartMill rating of HYLORIS PHARMACEUTICALS SA stock?
HYL.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is HYLORIS PHARMACEUTICALS SA (HYL.BR) stock traded?
HYL.BR stock is listed on the Euronext Brussels exchange.
What is the analyst forecast for HYL.BR stock?
7 analysts have analysed HYL.BR and the average price target is 13.84 EUR. This implies a price increase of 180.69% is expected in the next year compared to the current price of 4.93.
Can you provide the growth outlook for HYLORIS PHARMACEUTICALS SA?
The Revenue of HYLORIS PHARMACEUTICALS SA (HYL.BR) is expected to grow by 113.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.